Interventional Cardiology. Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
Department of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland.
Heart. 2022 Jun 24;108(14):1098-1106. doi: 10.1136/heartjnl-2021-319811.
Left atrial appendage (LAA) thrombus has heretofore been considered a contraindication to percutaneous LAA closure (LAAC). Data regarding its management are very limited. The aim of this study was to analyse the medical and invasive treatment of patients referred for LAAC in the presence of LAA thrombus.
This multicentre observational registry included 126 consecutive patients referred for LAAC with LAA thrombus on preprocedural imaging. Treatment strategies included intensification of antithrombotic therapy (IAT) or direct LAAC. The primary and secondary endpoints were a composite of bleeding, stroke and death at 18 months, and procedural success, respectively.
IAT was the preferred strategy in 57.9% of patients, with total thrombus resolution observed in 60.3% and 75.3% after initial and subsequent IAT, respectively. Bleeding complications and stroke during IAT occurred in 9.6% and 2.9%, respectively, compared with 3.8% bleeding and no embolic events in the direct LAAC group before the procedure. Procedural success was 90.5% (96.2% vs 86.3% in direct LAAC and IAT group, respectively, p=0.072), without cases of in-hospital thromboembolic complications. The primary endpoint occurred in 29.3% and device-related thrombosis was found in 12.8%, without significant difference according to treatment strategy. Bleeding complications at 18 months occurred in 22.5% vs 10.5% in the IAT and direct LAAC group, respectively (p=0.102).
In the presence of LAA thrombus, IAT was the initial management strategy in half of our cohort, with initial thrombus resolution in 60% of these, but with a relatively high bleeding rate (~10%). Direct LAAC was feasible, with high procedural success and absence of periprocedural embolic complications. However, a high rate of device-related thrombosis was detected during follow-up.
左心耳(LAA)血栓此前被认为是经皮 LAA 封堵(LAAC)的禁忌症。关于其治疗的数据非常有限。本研究的目的是分析存在 LAA 血栓的患者接受 LAAC 时的医学和侵入性治疗。
这项多中心观察性研究纳入了 126 例因 LAA 血栓而接受 LAAC 的连续患者。治疗策略包括强化抗血栓治疗(IAT)或直接 LAAC。主要和次要终点分别为 18 个月时的出血、卒中和死亡复合终点,以及程序成功。
IAT 是 57.9%患者的首选策略,初始和后续 IAT 后分别有 60.3%和 75.3%的患者完全溶解血栓。IAT 期间发生出血并发症和卒中分别为 9.6%和 2.9%,而直接 LAAC 组在手术前分别为 3.8%出血和无栓塞事件。程序成功率为 90.5%(直接 LAAC 和 IAT 组分别为 96.2%和 86.3%,p=0.072),无住院期间血栓栓塞并发症。主要终点发生在 29.3%的患者中,发现装置相关血栓形成在 12.8%的患者中,与治疗策略无显著差异。18 个月时出血并发症发生率分别为 IAT 组 22.5%和直接 LAAC 组 10.5%(p=0.102)。
在存在 LAA 血栓的情况下,IAT 是我们队列中一半患者的初始治疗策略,其中 60%的患者初始血栓溶解,但出血率相对较高(~10%)。直接 LAAC 是可行的,具有较高的程序成功率,且无围手术期栓塞并发症。然而,在随访期间发现了较高的装置相关血栓形成率。